[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"copeptin\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:copeptin":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,40,66],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100631120","serum-copeptin-as-biomarker-for-diagnosis-and-classification-of-polyuric-primary-monosymptomatic-nocturnal-enuresis-100631120",false,"NCT07496541","Serum Copeptin as Biomarker for Diagnosis and Classification of Polyuric Primary Monosymptomatic Nocturnal Enuresis","Inclusion Criteria:\n\n* 1.Age 5-18 years old. 2. No treatment has been received within 1 month prior to the trial. 3. Able to complete a 7-night urine diary and relevant research questionnaires for 2 days. 4. Guardians and the child themselves have agreed to participate in the study and have signed the informed consent form. 5. Meet the diagnostic criteria for PMNE as defined in the 2025 nocturnal enuresis guidelines: Age ≥ 5 years old, at least 1 episode of involuntary nocturnal urination per month for more than 3 months, without daytime lower urinary tract symptoms and organic urinary system disorders.\n\nExclusion Criteria:\n\n* 1\\. Patients under the age of 5; 2. Patients with daytime lower urinary tract symptoms or history of bladder dysfunction; 3. Patients with secondary nocturnal enuresis who have experienced at least 6 months of dry bed period; 4. Patients with chronic diseases.",true,"ALL","5 Years","18 Years",{"count":20,"type":21},180,"ESTIMATED","1 Day","OBSERVATIONAL","Primary monosymptomatic nocturnal enuresis (PMNE) is one of the most common urinary system problems in childhood. The exact pathological mechanism has not been fully elucidated yet, but excessive nocturnal urination is considered one of the core pathogenic mechanisms. Studies have found that a considerable number of PMNE patients have abnormal secretion of arginine vasopressin (AVP) at night. Currently, the \"gold standard\" for diagnosing nocturnal polyuria is through a voiding diary, which is cumbersome and the records may contain errors, and there are many inconveniences in clinical implementation. Therefore, finding objective and simple biomarkers to assist in diagnosis and classification is a current clinical research hotspot. Copeptin is the C-terminal fragment of the precursor protein of AVP and is released into the blood simultaneously at the same molar ratio as AVP, making it an ideal alternative biomarker for AVP. This study aims to systematically and deeply explore the diagnostic value of serum copeptin in PMNE, especially in its different subtypes (NP-PMNE vs. NNP-PMNE), analyze its correlation with clinical severity, and explore more precise detection strategies, in order to provide new and objective biological tools for the clinical management of PMNE.",[26,27],"Primary Monosymptomatic Nocturnal Enuresis","Copeptin","NOT_YET_RECRUITING","2026-03-23",{"date":31,"type":32},"2026-03-27","ACTUAL",{"date":34,"type":21},"2026-03-17",{"date":36,"type":21},"2029-01-31",{"name":38,"class":39},"The Children's Hospital of Zhejiang University School of Medicine","OTHER",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":18,"enrollmentInfo":48,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":50,"conditions":51,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":65},"100573113","the-trend-of-copeptin-levels-and-its-clinical-value-for-postoperative-cdi-in-pediatric-patients-after-nsi-in-icu-100573113","NCT06742060","The Trend of Copeptin Levels and Its Clinical Value for Postoperative CDI in Pediatric Patients After NSI in ICU","A Study on the Trend of Serum Copeptin Levels and Its Clinical Value for Postoperative Central Diabetes Insipidus in Pediatric Patients After Neurosurgical Intervention in Intensive Care Unit","Inclusion Criteria:\n\n* Male and female,age ≥29 days and \\\u003C18 years\n* After neurosurgical intervention\n* The patient agrees to comply with the requirements of the program, including follow-up visits and other related matters\n\nExclusion Criteria:\n\n* Structural diseases of the genitourinary system (with the possibility of nephrogenic diabetes insipidus)\n* Preoperative symptoms of diabetes insipidus\n* Diabetes mellitus (HbA1c \\>8.5%)\n* Drugs causing excessive drinking and urination (e.g., sodium-glucose cotransporter-2 inhibitors and diuretics)\n* Lack of follow-up data after 3 months","29 Days",{"count":49,"type":21},100,"Central diabetes insipidus (CDI),a disease caused by the decrease of AVP (a hormone involved in the control of water-electrolyte balance ) secretion and characerized by polyuria, is a common complication after neurosurgerical intervention and there is a lack of diagnostic criteria.Since the surgry casuses damage to patients' AVP-secreting neuronal cells, transient CDI (t-CDI) usually occurs 24-48h postoperatively and gradually resolves in about 10 days.However,permanent CDI (p-CDI) occurs in a small percentage of patients.Copeptin is a fragment of AVP, which has been shown to response the secretion of AVP.Multiple international studies have identified clinical applications for the use of copeptin to differentially diagnose adults with CDI , to assess electrolyte disturbances associated with AVP regulation, and to predict postoperative CDI after pituitary surgery.This study aims to investigate the trend of serum copeptin levels and its clinical value for postoperative CDI in pediatric patients after neurosurgerical intervention in ICU.",[52,53,27,54],"Diabetes Insipidus, Neurohypophyseal","Copeptin Blood Levels","Neurosurgical Intervention","RECRUITING","2026-02-12",{"date":58,"type":32},"2026-02-17",{"date":60,"type":32},"2024-11-22",{"date":62,"type":21},"2026-12-31",{"name":64,"class":39},"Children's Hospital of Fudan University",1,{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":16,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":77,"conditions":78,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":65},"100604793","endocan-and-copeptin-serum-levels-in-preterm-neonates-with-respiratory-distress-syndrome-100604793","NCT07154134","Endocan and Copeptin Serum Levels in Preterm Neonates With Respiratory Distress Syndrome","Comparative Study Between Endocan and Copeptin Serum Levels in Preterm Neonates With Respiratory Distress Syndrome","Inclusion Criteria:\n\n* Prematurity.\n* Gestational age between 28 and 36 weeks.\n* Suffering from respiratory distress syndrome.\n\nExclusion Criteria:\n\n* Intrauterine growth restriction (IUGR).\n* Hypoxic ischemic encephalopathy.\n* Multiple congenital anomalies.\n* Chromosomal abnormalities.\n* Preterm less than 28 weeks.\n* Neonates with a maternal history of chorioamnionitis (early sepsis).\n* Infant of diabetic mother.\n* Prelabor rupture of membranes (PROM)\\> 2 hours.","28 Weeks","36 Weeks",{"count":76,"type":21},40,"This work aims to investigate and compare the levels of serum endocan and serum copeptin on the first day of life and correlate their levels to the severity of respiratory distress in preterm neonates suffering from respiratory distress syndrome.",[79,27,80,81,82],"Endocan","Serum","Preterm Neonates","Respiratory Distress Syndrome","2025-08-27",{"date":85,"type":32},"2025-09-04",{"date":87,"type":32},"2025-07-10",{"date":89,"type":21},"2025-11-01",{"name":91,"class":39},"Tanta University"]